Ethics & Regulatory Compliance
At Triple Helix Science, our mission to pioneer curative gene therapies and longevity therapeutics is founded upon an unwavering commitment to human dignity, scientific diligence, patient safety, and sovereign regulatory compliance. We maintain the highest standards of international bioethics across every research division.
1. Declaration of Helsinki & Clinical Governance
All research initiatives, clinical trial protocols, and translational medical applications undertaken by Triple Helix Science adhere strictly to the World Medical Association Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP), and Good Laboratory Practice (GLP) regulations.
- Independent Institutional Review Board (IRB) or Research Ethics Committee (REC) review and approval is mandatory prior to protocol initiation.
- Comprehensive, voluntary informed consent is obtained from every clinical trial participant or legal surrogate without coercion.
- Independent Data and Safety Monitoring Boards (DSMB) evaluate longitudinal trial outcomes and safety metrics.
2. Ethical Boundaries in Genetic & Cellular Medicine
Triple Helix Science is dedicated exclusively to somatic cell gene therapeutics and regenerative medicine designed to alleviate severe human disease, arrest neurodegeneration, and reverse debilitating age-related functional decline.
- Strict institutional policy prohibiting human germline genetic modification or heritable genetic alterations.
- Ethical vector engineering prioritizing non-integrating and tissue-specific targeting mechanisms to minimize off-target effects.
- Commitment through BioHelix NP to ensure equitable access to transformative therapies for underserved global populations.
3. Sovereign Harmonization & Multi-Jurisdictional Oversight
We actively collaborate with regulatory bodies in every jurisdiction where our research hubs and clinical translation programs operate, including the United States FDA, European Medicines Agency (EMA), and UAE Ministry of Health and Prevention (MOHAP) / Department of Health (DoH).
- Adherence to sovereign healthcare goals, jurisdictional biosafety standards, and local clinical governance laws.
- Validated GMP-grade manufacturing facilities adhering to international sterility, purity, and viral clearance standards.
- Chain-of-custody tracking for all cellular and biological materials utilizing verified cold-chain logistics.
4. Anti-Corruption, Transparency & Investigator Integrity
We operate under a zero-tolerance policy regarding bribery, kickbacks, or unlawful inducements in connection with clinical research, government partnerships, or physician referrals.
- All clinical investigators and scientific advisory board members are required to complete annual conflict-of-interest declarations.
- Dedicated 24/7 confidential reporting channel for compliance, ethical, or safety concerns.
- Whistleblower protection ensuring researchers and collaborators can raise concerns without fear of retaliation.